J
James L. Kirkland
Researcher at Mayo Clinic
Publications - 322
Citations - 33834
James L. Kirkland is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Senescence & Adipose tissue. The author has an hindex of 76, co-authored 280 publications receiving 23328 citations. Previous affiliations of James L. Kirkland include Buck Institute for Research on Aging & University of Pittsburgh.
Papers
More filters
Posted ContentDOI
The efficacy of chemotherapy is limited by intratumoural senescent cells that persist through the upregulation of PD-L2
Selim Chaib,Jose Alberto Lopez-Dominguez,Marta Lalinde,Neus Prats,Ines Cambra Marin,Kathleen Meyer,M I Munoz,Mònica Aguilera,Lidia Mateo,Camille Stephan-Otto Attolini,Susana Llanos,Sandra Pérez Ramos,Marta Escorihuela,Fatima Al-Shahrour,Timothy P. Cash,Tamara Tchkonia,James L. Kirkland,Joaquín Arribas,Manuel Serrano +18 more
TL;DR: In this article , an unbiased proteomics approach was used to identify surface markers contributing to senescent cells immune evasion and the immune checkpoint inhibitor PD-L2 was found to upregulated across multiple senescent human and murine cells.
Journal ArticleDOI
A head‐to‐head comparison between senolytic therapies, dasatinib plus quercetin and fisetin, indicates sex‐ and genotype‐specific differences in translationally relevant outcomes: Developing topics
Valentina R. Garbarino,Sydney Tran,Jordan E Glassman,James L. Kirkland,Nicolas Musi,Sudha Seshadri,Miranda E. Orr +6 more
TL;DR: Results are reported from directly comparing D+Q to fisetin (FIS) to determine differences in efficacy, toxicity, and sex and genotype as they work to translate this therapy to clinical studies.
Book ChapterDOI
Monoaminergic regulation of the neuroendocrine transducer which controls acth secretion
G. R. Van Loon,R. Mascardo,Andrew Yau-Chik Shum,C. Kim,H. Datta,S. Green,James L. Kirkland,Michael J. Sole,A. Kamble +8 more
Journal ArticleDOI
Chronic HIV Infection and Aging: Application of a Geroscience-Guided Approach
Mary Clare Masters,Alan L. Landay,Paul D. Robbins,Tamara Tchkonia,James L. Kirkland,George A. Kuchel,Laura J. Niedernhofer,Frank J. Palella +7 more
TL;DR: It is speculated that targeting basic mechanisms of aging will improve overall health with age and drugs that target any of the pillars of aging, including metformin, rapamycin, and nicotinamide adenine dinucleotide precursors, may also slow the rate of onset of age-associated comorbidities and geriatric syndromes in PWH.
Journal ArticleDOI
Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability
Anoop M. Nambiar,Dean L. Kellogg,Jaime Justice,Martin M. Goros,Jonathan Gelfond,Rodolfo M. Pascual,Shahrukh K. Hashmi,Michal M. Masternak,Larissa G.P. Langhi Prata,Nathan K. LeBrasseur,Andrew H. Limper,Stephen B. Kritchevsky,Nicolas Musi,Tamara Tchkonia,James L. Kirkland +14 more
TL;DR: Kogod et al. as mentioned in this paper conducted an open-label single-arm pilot study of the senolytic combination of dasatinib and quercetin (D + Q) in patients with IPF, but lack of control group limited interpretation and next-stage trial planning.